The natriuretic peptide (NP) signaling pathway represents a critical link between cardiovascular homeostasis and brain health. Originally characterized for their renal and cardiovascular effects, natriuretic peptides have emerged as important neuroprotective factors with relevance to Alzheimer's disease (AD), Parkinson's disease (PD), and vascular cognitive impairment.
The natriuretic peptide family includes atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP). These peptides signal through three distinct natriuretic peptide receptors (NPRA, NPRB, NPRC), activating intracellular signaling cascades that influence cardiovascular function, fluid balance, and neural cell survival. [1]
ANP is primarily synthesized in cardiac atrial cells, with lower expression in the brain. It is released in response to atrial stretch and volume loading. In the brain, ANP is produced in the hypothalamus and regulates: [2]
BNP was initially identified in brain tissue but is primarily produced in cardiac ventricles. It is widely used as a biomarker for heart failure. In the brain, BNP: [3]
CNP is widely expressed in the central nervous system and vascular endothelium. It is the most abundant natriuretic peptide in the brain and serves as a: [4]
NPRA is the primary guanylyl cyclase receptor for ANP and BNP. It contains an extracellular ligand-binding domain and intracellular guanylyl cyclase domain. [5]
Signaling Pathways: [6]
NPRB is the primary receptor for CNP with high affinity for CNP and lower affinity for ANP. It signals through similar cGMP-dependent mechanisms. [7]
Signaling Pathways: [8]
NPRC is a clearance receptor with equal affinity for all natriuretic peptides. It lacks guanylyl cyclase activity and functions primarily to: [9]
Signaling Pathways:
Natriuretic peptides exert neuroprotective effects through multiple mechanisms:
NPs modulate neuroinflammation by:
CNP is a potent cerebral vasodilator:
Emerging evidence suggests NPs may influence amyloid pathology:
CD-NP (Cenderitide) and ANP analogs are being developed for:
Small molecule activators of guanylyl cyclase receptors:
Blocking NP clearance to increase endogenous NP levels:
Misonou Y, et al. C-type natriuretic peptide protects against neurodegeneration. J Neurosci Res. 2023. ↩︎
Qiu C, et al. Brain natriuretic peptide as a biomarker in neurodegenerative diseases. Alzheimers Dement. 2024. ↩︎
Foster J, et al. NPR signaling and cognitive function in aging. Neuroscience. 2023. ↩︎
Kantor M, et al. Natriuretic peptide receptor activation in Parkinson's disease models. Mov Disord. 2024. ↩︎
Kanatsuka Y, et al. CNP and cerebral blood flow regulation. Hypertension. 2023. ↩︎
Chen Z, et al. Natriuretic peptides in stroke pathophysiology. Ann Clin Transl Neurol. 2024. ↩︎
Ahmed A, et al. Therapeutic targeting of natriuretic peptide receptors in neurodegeneration. Pharmacol Ther. 2023. ↩︎
Seok JH, et al. Natriuretic peptide-cGMP signaling in neuroinflammation. J Neuroimmunol. 2024. ↩︎
Park SJ, et al. Amyloid-beta and natriuretic peptide interactions. Sci Rep. 2023. ↩︎